Coherus Q1 2025: LOQTORZI rev $7.3M, net loss $47.4M; UDENYCA divestiture closed

Coherus Oncology, Inc.

2025-Q1 EPS reported -$0.49 revenue$7,599,000

Continuing ops net loss $47.4M ($0.41 diluted); non-GAAP net loss $40.9M ($0.35).
LOQTORZI net revenue $7.3M, patient demand grew >15% vs Q4 2024.
UDENYCA divestiture closed April 2025 for upfront $483.4M, total up to $558.4M.
CHS-114 Phase 1b shows confirmed partial response in PD-1 refractory HNSCC; proof of mechanism.
Casdozokitug Phase 2 randomized trial in 1L HCC enrolling; data readout expected 1H 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.